Published in BMC Res Notes on May 24, 2014
International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol (2004) 14.06
Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol (1998) 5.69
Juvenile idiopathic arthritis. Lancet (2007) 5.64
Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med (2000) 4.76
2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) (2011) 3.66
A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum (2007) 3.32
Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum (2010) 2.29
A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum (2005) 2.20
Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res (2001) 2.06
Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol (2007) 1.82
A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum (2004) 1.71
Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss. Am J Ophthalmol (2007) 1.66
Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum (2005) 1.59
Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology (2010) 1.54
Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol (2006) 1.47
Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford) (2006) 1.47
Risk factors for ocular complications and poor visual acuity at presentation among patients with uveitis associated with juvenile idiopathic arthritis. Am J Ophthalmol (2006) 1.43
An evaluation of baseline risk factors predicting severity in juvenile idiopathic arthritis associated uveitis and other chronic anterior uveitis in early childhood. Br J Ophthalmol (2002) 1.42
Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology (2012) 1.39
Epidemiology and course of disease in childhood uveitis. Ophthalmology (2009) 1.35
Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken) (2011) 1.24
Adalimumab therapy for childhood uveitis. J Pediatr (2006) 1.20
Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford) (2008) 1.20
Juvenile idiopathic arthritis. Autoimmun Rev (2005) 1.18
Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study. Arthritis Rheum (2007) 1.16
Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology. Int Ophthalmol (2011) 1.15
Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxford) (2005) 1.09
Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol (2012) 1.07
Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry. J Rheumatol (2012) 1.06
Uveitis in juvenile chronic arthritis: incidence, clinical features and prognosis. Eye (Lond) (1988) 1.05
Factors related to severe uveitis at diagnosis in children with juvenile idiopathic arthritis in a screening program. Am J Ophthalmol (2003) 1.02
Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. Curr Med Res Opin (2004) 1.02
Chronic anterior uveitis in children: clinical characteristics and complications. Am J Ophthalmol (2009) 0.98
Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin Ophthalmol (2011) 0.96
New advances in the management of juvenile idiopathic arthritis--2: the era of biologicals. Arch Dis Child Educ Pract Ed (2009) 0.88
Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature. Ocul Immunol Inflamm (2006) 0.88
Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis. Pediatr Rheumatol Online J (2013) 0.85
Adalimumab for juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol (2013) 0.84
Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons. Ann Rheum Dis (2012) 0.84
Functional status in severe juvenile idiopathic arthritis in the biologic treatment era: an assessment in a French paediatric rheumatology referral centre. Rheumatology (Oxford) (2012) 0.82
The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a systematic review. Semin Arthritis Rheum (2013) 0.82
Growth in juvenile idiopathic arthritis: the role of inflammation. Clin Exp Rheumatol (2011) 0.81
Juvenile idiopathic arthritis: new insights into classification, measures of outcome, and pharmacotherapy. Paediatr Drugs (2011) 0.81
Anti-TNF-alpha therapy for uveitis: Behçet and beyond. Eye (Lond) (2005) 0.80
Ocular threat in juvenile idiopathic arthritis. Joint Bone Spine (2009) 0.80
Lung ultrasound characteristics of community-acquired pneumonia in hospitalized children. Pediatr Pulmonol (2012) 3.63
Lung ultrasound in bronchiolitis: comparison with chest X-ray. Eur J Pediatr (2011) 3.45
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis (2010) 2.71
Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in basophils. Nat Immunol (2009) 1.97
Serum amyloid-A in Behçet's disease. Clin Rheumatol (2014) 1.47
The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency. J Allergy Clin Immunol (2005) 1.43
Sensorineural hearing loss in primary antibody deficiency disorders. J Pediatr (2008) 1.42
Profound T-cell defects in Dubowitz syndrome. Pediatr Allergy Immunol (2014) 1.39
Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken) (2011) 1.24
Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis: pathogenetic and clinical implications. Arthritis Rheum (2006) 1.13
Differentiating PFAPA syndrome from monogenic periodic fevers. Pediatrics (2009) 1.12
Mutational analysis of human BAFF receptor TNFRSF13C (BAFF-R) in patients with common variable immunodeficiency. J Clin Immunol (2005) 1.09
Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra. J Pediatr (2010) 1.07
Combined decrease of defined B and T cell subsets in a group of common variable immunodeficiency patients. Clin Immunol (2006) 1.00
Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis. Ann Rheum Dis (2010) 0.99
Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis. Clin Exp Rheumatol (2011) 0.98
MVK mutations and associated clinical features in Italian patients affected with autoinflammatory disorders and recurrent fever. Eur J Hum Genet (2005) 0.95
Mutations of the Igbeta gene cause agammaglobulinemia in man. J Exp Med (2007) 0.95
Comparison of esophageal pH and multichannel intraluminal impedance testing in pediatric patients with suspected gastroesophageal reflux. J Pediatr Gastroenterol Nutr (2010) 0.93
Clinical impact of MEFV mutations in children with periodic fever in a prevalent western European Caucasian population. Ann Rheum Dis (2012) 0.93
Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev (2012) 0.92
Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome. Clin Rheumatol (2014) 0.91
Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. Arthritis Rheum (2005) 0.91
The translationally controlled tumor protein is a novel calcium binding protein of the human placenta and regulates calcium handling in trophoblast cells. Biol Reprod (2005) 0.90
Body experiences, emotional competence, and psychosocial functioning in juvenile idiopathic arthritis. Rheumatol Int (2013) 0.89
The effect of strong static magnetic field on lymphocytes. Bioelectromagnetics (2003) 0.88
Mutations of the X-linked lymphoproliferative disease gene SH2D1A mimicking common variable immunodeficiency. Eur J Pediatr (2002) 0.86
Update on laser-evoked potential findings in fibromyalgia patients in light of clinical and skin biopsy features. J Neurol (2013) 0.85
Allele *1 of HS1.2 enhancer associates with selective IgA deficiency and IgM concentration. J Immunol (2009) 0.85
Autosomal recessive agammaglobulinemia: novel insights from mutations in Ig-beta. Curr Allergy Asthma Rep (2008) 0.85
Protective effect of augmenter of liver regeneration on hydrogen peroxide-induced apoptosis in SH-SY5Y human neuroblastoma cells. Free Radic Res (2009) 0.85
The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension. Curr Med Res Opin (2005) 0.84
Early-onset sarcoidosis caused by a rare CARD15/NOD2 de novo mutation and responsive to infliximab: a case report with long-term follow-up and review of the literature. Clin Rheumatol (2014) 0.83
Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome: Results From an International Retrospective Multicenter Study. Medicine (Baltimore) (2015) 0.83
Interleukin-1 Inhibition in Behçet's disease. Isr Med Assoc J (2016) 0.83
A novel immunodeficiency characterized by the exclusive presence of transitional B cells unresponsive to CpG. Immunology (2007) 0.82
[Side effects of anti-TNFalpha therapy in juvenile idiopathic arthritis]. Reumatismo (2006) 0.81
Chemerin/ChemR23 pathway: a system beyond chemokines. Arthritis Res Ther (2011) 0.81
Role of the nitric oxide/cyclic GMP/Ca2+ signaling pathway in the pyrogenic effect of interleukin-1beta. Mol Neurobiol (2002) 0.81
Update on treatment of Marshall's syndrome (PFAPA syndrome): report of five cases with review of the literature. Ann Otol Rhinol Laryngol (2003) 0.81
Putative Role of Serum Amyloid-A and Proinflammatory Cytokines as Biomarkers for Behcet's Disease. Medicine (Baltimore) (2015) 0.81
Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Rheumatol Int (2015) 0.81
Paradoxical mucocutaneous flare in a case of Behçet's disease treated with tocilizumab. Clin Rheumatol (2014) 0.80
Metabolic activity of chondrocytes in human osteoarthritis as a result of cell-extracellular matrix interactions. Semin Arthritis Rheum (2005) 0.79
Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate. Clin Rheumatol (2014) 0.79
Mutational analysis of human BLyS in patients with common variable immunodeficiency. J Clin Immunol (2006) 0.79
Efficacy and Safety of Intravenous Immunoglobulin Treatment in Refractory Behcet's Disease with Different Organ Involvement: A Case Series. Isr Med Assoc J (2016) 0.78
Is there a role for TNFα antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique. Clin Exp Rheumatol (2011) 0.78
Aicardi-Goutieres syndrome, a rare neurological disease in children: a new autoimmune disorder? Autoimmun Rev (2012) 0.78
Proinflammatory Cytokines and Antiskin Autoantibodies in Patients With Inherited Epidermolysis Bullosa. Medicine (Baltimore) (2015) 0.77
Juvenile polyp. Eur J Pediatr (2013) 0.76
Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response. Drug Dev Res (2014) 0.76
Extracorporeal shock waves down-regulate the expression of interleukin-10 and tumor necrosis factor-alpha in osteoarthritic chondrocytes. BMC Musculoskelet Disord (2008) 0.75
Response to lung ultrasound as an additional imaging tool for the evaluation of pneumonia. Pediatr Pulmonol (2014) 0.75
Sensitivity and feasibility of lung ultrasound in bronchiolitis -- reply to the correspondence letter by Catalano. Eur J Pediatr (2013) 0.75
The change in Ig regulation from children to adults disconnects the correlation with the 3'RR hs1.2 polymorphism. BMC Immunol (2014) 0.75
Human immunodeficiency virus-1 and rheumatoid arthritis: a puzzling association. J Rheumatol (2003) 0.75
Reply to the correspondence letter by P. Toma: usefulness of ultrasound findings in bronchiolitis. Eur J Pediatr (2013) 0.75
The effect of exposure to high flux density static and pulsed magnetic fields on lymphocyte function. Bioelectromagnetics (2003) 0.75
Interleukin-1: Ariadne's Thread in Autoinflammatory and Autoimmune Disorders. Isr Med Assoc J (2015) 0.75
Paradoxical Pustular Psoriasis in a Patient With Psoriatic Arthritis on Secukinumab Treatment. J Clin Rheumatol (2020) 0.75
The protean ocular involvement in monogenic autoinflammatory diseases: state of the art. Clin Rheumatol (2015) 0.75
Cutaneous lesions as presenting symptoms of primary biliary cirrhosis: an undifferentiated connective tissue disease-like onset. Clin Rheumatol (2005) 0.75
Digital laser doppler flowmetry may discriminate "limited" from "diffuse" systemic sclerosis. Microvasc Res (2010) 0.75